{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:16:26Z","timestamp":1793837786441,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ijantimicag.2024.107293","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T07:24:08Z","timestamp":1722583448000},"page":"107293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia"],"prefix":"10.1016","volume":"64","author":[{"given":"Peili","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107293_bib0001","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fphar.2020.00829","article-title":"Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections","volume":"11","author":"Wang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0002","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Critical Care (London, England)"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0003","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsinfecdis.5b00085","article-title":"Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant gram-negative bacteria","volume":"1","author":"Roberts","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0004","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jac\/dks435","article-title":"Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?","volume":"68","author":"Shekar","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0034-1398490","article-title":"Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development","volume":"36","author":"Abdul-Aziz","year":"2015","journal-title":"Semin Resp Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0006","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0007","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0008","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jinf.2021.01.006","article-title":"Acute toxicity is a dose-limiting factor for intravenous polymyxin B: a safety and pharmacokinetic study in healthy Chinese subjects","volume":"82","author":"Liu","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0009","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1093\/cid\/ciaa121","article-title":"Committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints","volume":"71","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1631\/jzus.B2200466","article-title":"Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic","volume":"24","author":"Liu","year":"2023","journal-title":"J Zhejiang University Sci B"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0011","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bcpt.12820","article-title":"Voriconazole concentrations in plasma and epithelial lining fluid after inhalation and oral treatment","volume":"121","author":"Andersen","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0012","doi-asserted-by":"crossref","first-page":"115291","DOI":"10.1016\/j.jpba.2023.115291","article-title":"Determination of polymyxin B in human plasma and epithelial lining fluid using LC-MS\/MS and its clinical application in therapeutic drug monitoring","volume":"227","author":"Zhang","year":"2023","journal-title":"J Pharmaceut Biomed Analysis"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0013","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","article-title":"Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution","volume":"60","author":"Rennard","year":"1986","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0014","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1128\/AAC.01836-13","article-title":"Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage","volume":"58","author":"Naderer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4155\/bio-2020-0051","article-title":"Therapeutic drug monitoring of polymyxin B by LC-MS\/MS in plasma and urine","volume":"12","author":"Liu","year":"2020","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0016","first-page":"3291","article-title":"New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection","volume":"70","author":"Cheah","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0017","doi-asserted-by":"crossref","first-page":"106588","DOI":"10.1016\/j.ijantimicag.2022.106588","article-title":"Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia","volume":"59","author":"Gkoufa","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0018","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-0041-1740340","article-title":"Nebulized antibiotics for healthcare- and ventilator-associated pneumonia","volume":"43","author":"Boisson","year":"2022","journal-title":"Semin Resp Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0019","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1172\/JCI107490","article-title":"Prevention of gram-negative bacillary pneumonia using aerosol polymyxin as prophylaxis. I. Effect on the colonization pattern of the upper respiratory tract of seriously ill patients","volume":"52","author":"Greenfield","year":"1973","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0020","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/jac\/dkh369","article-title":"Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections","volume":"54","author":"Sobieszczyk","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0021","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1684-1182(10)60050-3","article-title":"Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan","volume":"43","author":"Lin","year":"2010","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0022","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1086\/657242","article-title":"Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study","volume":"51","author":"Kofteridis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0023","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.medin.2011.01.013","article-title":"Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients","volume":"35","author":"P\u00e9rez-Pedrero","year":"2011","journal-title":"Medicina intensiva"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0024","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s10156-012-0430-7","article-title":"Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?","volume":"18","author":"Kalin","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0025","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1378\/chest.13-1018","article-title":"Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria","volume":"144","author":"Tumbarello","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0026","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/2319-4170.132879","article-title":"Influencing factors of successful eradication of multidrug-resistant Acinetobacter baumannii in the respiratory tract with aerosolized colistin","volume":"37","author":"Chen","year":"2014","journal-title":"Biomed J"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0027","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcrc.2017.04.004","article-title":"Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii","volume":"40","author":"Jang","year":"2017","journal-title":"J Crit Care"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0028","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12941-016-0123-7","article-title":"Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?","volume":"15","author":"Demirdal","year":"2016","journal-title":"Annals Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0029","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00134-012-2628-7","article-title":"Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients","volume":"38","author":"Athanassa","year":"2012","journal-title":"Intens Care Med"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijantimicag.2014.09.010","article-title":"Inhaled colistimethate sodium in ventilator-associated tracheobronchitis due to multidrug-resistant gram-negative bacteria","volume":"45","author":"Maskin","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0031","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/jac\/dkz356","article-title":"Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia","volume":"74","author":"Ben\u00edtez-Cano","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0032","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/15321819.2019.1696818","article-title":"Comparison of two therapeutic approaches for the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter: a randomized clinical trial study","volume":"41","author":"Khorvash","year":"2020","journal-title":"J Immun Immunochem"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0033","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J Antimicrobial Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13613-016-0127-7","article-title":"Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial","volume":"6","author":"Abdellatif","year":"2016","journal-title":"Annals Intens Care"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2478\/jccm-2020-0044","article-title":"The susceptibility of MDR-K. Pneumoniae to polymyxin B plus its nebulised form versus polymyxin B alone in critically ill South Asian patients","volume":"7","author":"Hasan","year":"2021","journal-title":"J Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0036","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13613-022-01033-5","article-title":"Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case-control study","volume":"12","author":"Liu","year":"2022","journal-title":"Annals Intens Care"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0037","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijantimicag.2014.07.004","article-title":"Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic review and meta-analysis","volume":"44","author":"Gu","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0038","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jinf.2018.02.002","article-title":"Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: a systematic review and meta-analysis","volume":"76","author":"Vardakas","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0039","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3390\/microorganisms9061154","article-title":"Nebulized colistin in ventilator-associated pneumonia and tracheobronchitis: historical background, pharmacokinetics and perspectives","volume":"9","author":"Zhu","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0040","first-page":"e00211","article-title":"Aerosolized polymyxin B for treatment of respiratory tract infections: determination of pharmacokinetic-pharmacodynamic indices for aerosolized polymyxin B against Pseudomonas aeruginosa in a mouse lung infection model","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0041","first-page":"1194","article-title":"Chinese expert consensus on polymyxins in the clinical practice","volume":"31","author":"Sun","year":"2019","journal-title":"Chinese Critical Care Emergency Medicine"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0043","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1086\/518706","article-title":"Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B","volume":"45","author":"Knueppel","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0044","first-page":"Fd01","article-title":"Polymyxin B-induced diffuse cutaneous hyperpigmentation","volume":"11","author":"Lahiry","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12098-015-1798-z","article-title":"Polymyxin B induced generalized hyperpigmentation in neonates","volume":"83","author":"Gothwal","year":"2016","journal-title":"Ind J Pediatr"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0046","doi-asserted-by":"crossref","first-page":"1122310","DOI":"10.3389\/fphar.2023.1122310","article-title":"Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients","volume":"14","author":"Liang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0047","doi-asserted-by":"crossref","first-page":"106599","DOI":"10.1016\/j.ijantimicag.2022.106599","article-title":"Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration","volume":"60","author":"Wang","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0048","doi-asserted-by":"crossref","first-page":"106214","DOI":"10.1016\/j.ejps.2022.106214","article-title":"Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with\/without continuous renal replacement therapy","volume":"175","author":"Luo","year":"2022","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0049","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/17425255.2019.1563596","article-title":"Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients","volume":"15","author":"Cheng","year":"2019","journal-title":"Expert Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0050","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkx409","article-title":"Pharmacokinetics\/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models","volume":"73","author":"Landersdorfer","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0051","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13054-023-04326-8","article-title":"Trough concentration may not be a good target for polymyxin B therapeutic drug monitoring","volume":"27","author":"Zhao","year":"2023","journal-title":"Critical Care (London, England)"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00483-18","article-title":"Personalizing polymyxin B dosing using an adaptive feedback control algorithm","volume":"62","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0053","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/AAC.01705-13","article-title":"Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration","volume":"58","author":"Yapa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107293_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00973-17","article-title":"Pulmonary pharmacokinetics of colistin following administration of dry powder aerosols in rats","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T17:42:15Z","timestamp":1732556535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924002097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0924857924002097"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107293","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107293"}}